Evaluating WEGOVY treatment for adults with genetic obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on adults diagnosed with monogenic obesity, a rare genetic condition affecting energy balance. Participants who have started treatment with Semaglutide (WEGOVY) will be monitored to evaluate the effectiveness of this therapy in managing their condition. The study aims to gather real-life data on the treatment's impact on weight management and associated complications, addressing the need for effective therapeutic options in this challenging patient population. By analyzing the outcomes, the study seeks to inform future clinical practices for managing monogenic obesity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients (≥12 years) having already initiated a treatment with SEMAGLUTIDE (regardless of the context: early access, routine care, self-financing, or exceptional reimbursement) or with a physician's decision to initiate treatment in the standard care. All patients having initiated treatment will be proposed to participate, including those having already stopped the treatment at the time of study initiation.
* Confirmation of monogenic obesity, as practiced in clinical routine, regardless of current classification (i.e., pathogenic, likely pathogenic, variant of uncertain significance \[VUS\], or benign) in a gene with leptin-melanocortin pathway described in PNDS (https://www.has-sante.fr/jcms/p\_3280217/fr/generique-obesites-de-causes-rares). ) For patients with VUS or benign variants, inclusion is conditional on the availability of a polygenic risk score (PRS)
* Patients duly informed and not objecting to participate in the study. For patients ≥12 years \<18 years Parents duly informed and not objecting that their child taking part in the study
* Patients affiliated to a social security scheme or State Medical Assistance (AME).

Exclusion Criteria:

* Pregnant and breastfeeding women

Where it's running

• CHU Pitié Salpêtrière - APHP
  Paris, France Recruiting
• Centre de référence Syndrome de Prader-Willi et autres obésités avec troubles du comportement alimentaire (PRADORT). Service de Nutrition, GH Pitié-Salpêtrière, APHP
  Paris, France Not yet recruiting

Study contacts

• Principal investigator: Christine POITOU-BERNERT, MD,PhD — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Christine POITOU-BERNERT, MD,PhD
• Email: christine.poitou-bernert@aphp.fr
• Phone: +33(0)142175771

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Once-weekly semaglutide for weight loss in adolescents with monogenic obesity

  This study tests whether once-weekly semaglutide 2.4 mg together with a reduced-calorie diet and increased activity helps adolescents with monogenic obesity lose weight, reduce hunger, and improve quality of life over 68 weeks.

  Recruiting University of Ulm · Paris and 6 other locations · NCT07302802

• Mibavademab for obesity caused by leptin (LEP) gene mutations in children, adolescents, and adults

  This trial will try mibavademab in children, adolescents, and adults with leptin gene–related obesity to help control body weight and check safety.

  Recruiting at 3 sites Phase 3 Regeneron Pharmaceuticals · Ulm and 2 other locations · NCT07220772

• Diffusion MRI to map nerve lesions in obstetric brachial plexus palsy

  This study tests diffusion MRI and tractography to better understand nerve injuries in people with obstetric brachial plexus palsy.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07767708

• Long-term心理 and cognitive check after stem cell transplant for immune deficiencies

  This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07766304

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Gut microbes and autoinflammatory diseases: how they may be linked

  This study tests whether gut bacteria and their byproducts relate to digestive and inflammatory symptoms in people with autoinflammatory diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07718555

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.